Publication number: 20230406946
Abstract: The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.
Type:
Application
Filed:
August 22, 2022
Publication date:
December 21, 2023
Inventors:
Nicholas S. WILSON, Jeremy D. WAIGHT, Gerd RITTER, David SCHAER, Daniel HIRSCHHORN-CYMERMAN, Taha MERGHOUB, Ekaterina V. BREOUS-NYSTROM, Volker SEIBERT, Takemasa TSUJI, Olivier LÉGER, Dennis J. UNDERWOOD, Marc VAN DIJK
Publication number: 20230399413
Abstract: The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.
Type:
Application
Filed:
August 22, 2022
Publication date:
December 14, 2023
Inventors:
Nicholas S. WILSON, Jeremy D. WAIGHT, Gerd RITTER, David SCHAER, Daniel HIRSCHHORN-CYMERMAN, Taha MERGHOUB, Ekaterina V. BREOUS-NYSTROM, Volker SEIBERT, Takemasa TSUJI, Olivier LÉGER, Dennis J. UNDERWOOD, Marc VAN DIJK